BR112012021995A8 - Composição,célula hospedeira bacteriana não patogênica, método para a produção de um sulfato de condroitina,condroitina, composição e anticorpo ou fragmento de anticorpo - Google Patents

Composição,célula hospedeira bacteriana não patogênica, método para a produção de um sulfato de condroitina,condroitina, composição e anticorpo ou fragmento de anticorpo

Info

Publication number
BR112012021995A8
BR112012021995A8 BR112012021995A BR112012021995A BR112012021995A8 BR 112012021995 A8 BR112012021995 A8 BR 112012021995A8 BR 112012021995 A BR112012021995 A BR 112012021995A BR 112012021995 A BR112012021995 A BR 112012021995A BR 112012021995 A8 BR112012021995 A8 BR 112012021995A8
Authority
BR
Brazil
Prior art keywords
composition
chondroitin
antibody
production
host cell
Prior art date
Application number
BR112012021995A
Other languages
English (en)
Other versions
BR112012021995A2 (pt
Inventor
A Weaver Craig
Miyamoto Kentaro
Minamisawa Toshikazu
H Doherty Daniel
Original Assignee
Dsm Ip Assets Bv
Seikagaku Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv, Seikagaku Kogyo Co Ltd filed Critical Dsm Ip Assets Bv
Publication of BR112012021995A2 publication Critical patent/BR112012021995A2/pt
Publication of BR112012021995A8 publication Critical patent/BR112012021995A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)

Abstract

CONSTRUÇÃO, CÉLULA HOSPEDEIRA BACTERIANA NÃO PATOGÊNICA, MÉTODO PARA A PRODUÇÃO DE UM SULFATO DE CONDROITINA, COMPOSIÇÃO E ANTICORPO OU FRAGMENTO DE ANTICORPO. A invenção está relacionada ao campo da tecnologia de DNA recombinante para a produção de condroitina, incluindo a produção de sulfato de condroitina por meio de uma combinação de fermentação bacteriana recombinante e sulfatação pós-fermentação.
BR112012021995A 2010-03-01 2011-03-01 Composição,célula hospedeira bacteriana não patogênica, método para a produção de um sulfato de condroitina,condroitina, composição e anticorpo ou fragmento de anticorpo BR112012021995A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30940710P 2010-03-01 2010-03-01
PCT/US2011/026748 WO2011109438A1 (en) 2010-03-01 2011-03-01 Compositions and methods for bacterial production of chondroitin

Publications (2)

Publication Number Publication Date
BR112012021995A2 BR112012021995A2 (pt) 2015-10-06
BR112012021995A8 true BR112012021995A8 (pt) 2018-01-02

Family

ID=44542545

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012021995A BR112012021995A8 (pt) 2010-03-01 2011-03-01 Composição,célula hospedeira bacteriana não patogênica, método para a produção de um sulfato de condroitina,condroitina, composição e anticorpo ou fragmento de anticorpo

Country Status (8)

Country Link
US (2) US8697398B2 (pt)
EP (1) EP2542686B1 (pt)
JP (1) JP5875531B2 (pt)
KR (1) KR101848102B1 (pt)
CN (1) CN102869782B (pt)
BR (1) BR112012021995A8 (pt)
ES (1) ES2661593T3 (pt)
WO (1) WO2011109438A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5875531B2 (ja) 2010-03-01 2016-03-02 生化学工業株式会社 コンドロイチンの細菌生産のための組成物および方法
SI2591127T1 (sl) 2010-07-09 2017-12-29 Gnosis S.P.A. Biotehnološka proizvodnja hondroitina
WO2013172154A1 (ja) * 2012-05-17 2013-11-21 東洋紡株式会社 担子菌酵母変異体
ITMI20120896A1 (it) 2012-05-23 2013-11-24 Bongulielmi Reto Condroitina per uso in medicina
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
US9902756B2 (en) 2012-11-16 2018-02-27 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Gonorrheal MtrE peptides and vaccines
US20150247174A1 (en) * 2012-12-28 2015-09-03 Anhui Huaheng Bioengineering Co., Ltd, Engineering bacteria for producing dl-alanine and method for producing dl-alanine by using engineering bacteria
EP3053599A4 (en) * 2013-09-30 2017-06-14 Seikagaku Corporation Method for improving blood persistence of protein
FR3016637B1 (fr) * 2014-01-23 2020-11-27 Centre Nat Rech Scient Procede de production in vivo de glycosaminoglycane
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3050973A1 (en) * 2015-01-30 2016-08-03 Jennewein Biotechnologie GmbH Fermentation process for producing monosaccharides in free form from nucleotide-activated sugars
US10259889B2 (en) 2015-03-31 2019-04-16 Seikagaku Corporation Method for sulfating glycosaminoglycan
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
IT202000013633A1 (it) * 2020-06-08 2021-12-08 Vivatis Pharma Gmbh Processo di estrazione di una condroitina solfato da un fungo, una condroitina solfato di origine vegetale e suo uso
EP4067487A1 (en) 2021-04-01 2022-10-05 Givaudan SA Chondroitin-producing recombinant cell

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104601A1 (en) 1999-04-01 2003-06-05 Deangelis Paul L. Chondroitin synthase gene and methods of making and using same
WO2000027437A2 (en) 1998-11-11 2000-05-18 The Board Of Regents Of The University Of Oklahoma Polymer grafting by polysaccharide synthases
US20060105431A1 (en) 1998-11-11 2006-05-18 Deangelis Paul L Polymer grafting by polysaccharide synthases using artificial sugar acceptors
US6235510B1 (en) 1999-08-18 2001-05-22 Smithkline Beecham Corporation ppGaNTase-T6
EP1233072B1 (en) 1999-11-25 2006-08-02 Yamasa Corporation Novel use of uridine diphosphate glucose 4-epimerase
DE10019881A1 (de) * 2000-04-20 2001-11-15 Gerhard Miksch Verfahren zur Überexpression und extrazellulären Produktion bakterieller Phytasen in Escherichia coli
EP1470235A4 (en) 2001-07-13 2008-05-21 Univ Oklahoma GLYCOSAMINOGLYCAN POLYMERS AND METHODS OF PREPARING AND USING THE SAME
JP4702819B2 (ja) 2001-08-01 2011-06-15 生化学工業株式会社 コンドロイチン合成酵素
JP4101548B2 (ja) 2001-08-10 2008-06-18 生化学工業株式会社 コンドロイチン合成酵素及びそれをコードするdna
JP4338038B2 (ja) 2002-05-31 2009-09-30 生化学工業株式会社 コンドロイチン合成酵素および該酵素をコードする核酸
JP4333880B2 (ja) 2002-05-31 2009-09-16 生化学工業株式会社 コンドロイチン合成酵素および該酵素をコードするdna
AU2005287397A1 (en) 2004-06-30 2006-03-30 Paul L. Deangelis Methods of selectively treating diseases with specific glycosaminoglycan polymers
ES2299284B1 (es) * 2004-11-04 2009-04-16 Universidad Pablo De Olavide Control de la expresion genica mediante el uso de un atenuador de la transcripcion.
US20080219960A1 (en) * 2004-12-16 2008-09-11 Masja Nathalie Nierop Groot Novel Efficient Production Process for Capsular Polysaccharides of Pathogenic Grampositive Bacteria by Heterologous Expression and Secretion of Complex Polysaccharides in Non-Pathogenic, Non-Invasive Gram-Positive Bacteria
JP5176114B2 (ja) * 2005-06-06 2013-04-03 フェネックス インコーポレイテッド 細菌宿主細胞におけるマンニトール誘導のプロモーター系
EP1964924B1 (en) 2005-12-15 2015-09-30 Seikagaku Corporation Long-chain chondroitin sugar chain and method for producing the same and method for promoting synthesis of chondroitin
EP2690178B1 (en) 2006-10-03 2021-12-22 The Board Of Regents Of The University Of Oklahoma Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
WO2008133350A1 (en) * 2007-04-24 2008-11-06 Seikagaku Corporation Chondroitin-producing bacterium and method of producing chondroitin
JP5875531B2 (ja) 2010-03-01 2016-03-02 生化学工業株式会社 コンドロイチンの細菌生産のための組成物および方法
SI2591127T1 (sl) 2010-07-09 2017-12-29 Gnosis S.P.A. Biotehnološka proizvodnja hondroitina

Also Published As

Publication number Publication date
CN102869782A (zh) 2013-01-09
KR101848102B1 (ko) 2018-04-11
JP2013520995A (ja) 2013-06-10
EP2542686B1 (en) 2018-01-03
CN102869782B (zh) 2015-11-25
EP2542686A4 (en) 2014-03-26
BR112012021995A2 (pt) 2015-10-06
WO2011109438A1 (en) 2011-09-09
US20110244520A1 (en) 2011-10-06
ES2661593T3 (es) 2018-04-02
US9175293B2 (en) 2015-11-03
US8697398B2 (en) 2014-04-15
JP5875531B2 (ja) 2016-03-02
EP2542686A1 (en) 2013-01-09
KR20130055571A (ko) 2013-05-28
US20140296505A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
BR112012021995A8 (pt) Composição,célula hospedeira bacteriana não patogênica, método para a produção de um sulfato de condroitina,condroitina, composição e anticorpo ou fragmento de anticorpo
BR112016023304A2 (pt) célula hospedeira recombinante engendrada para superexpressar proteínas auxiliares
EP4036240A3 (en) Transduction buffer
BR112013018307A2 (pt) polipeptídeo isolado, composição, polinucleotídeo isolado, construto de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, métodos para produzir um polipeptídeo e uma proteína, e, processos para degradar um material celulósico, para sintetizar um produto de fermentação, e para fermentar um material celulósico.
BR112012000260A2 (pt) polipeptídeo isolado, composição, polinucleotídeo isolado, célula hospedeira, métodos para produzir um polipeptídeo, uma proteína e um produto de fermentação, para inibir a expressão de um polopeptídeo, para degradar ou converter um material celulósico, e para fermentar um material celulósico, planta, parte de planta ou célula de planta, e, molécula de rna inibidora de filamento duplo.
CL2011002611A1 (es) Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17.
GB201020995D0 (en) Biological materials and uses thereof
BR112012002137A2 (pt) método para um polipeptídeo e/ou vírus de interesse em uma cultura de célula contínua,e, composição
CL2013001403A1 (es) Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
BR112013019038A2 (pt) polipeptídeo isolado, polinucleotídeo isolado, célula hospedeira recombinante, métodos de produzir o polipeptídeo, de produzir um mutante de uma célula parental, de inibir a expressão de um polipeptídeo, de produzir uma proteína, para degradar ou converter um material celulósico, de produzir um produto de fermentação, de fermentar um material celulósico, planta transgênica, parte da planta ou célula de planta transformada com um polinucleotídeo, molécula de rna inibitório dupla fita (rnads), e, formulação completa de caldo ou composição de cultura de células.
BR112013016830A2 (pt) polipeptídeo isolado, polinucleotídeo isolado, método de produzir o polipeptídeo, de produzir um mutante de uma célula parental, de inibir a expressão de um polipeptídeo, de produzir uma proteína, de degradar ou converter um material celulósico, de produzir um produto de fermentação e de fermentar um material celulósico, planta transgênica, parte da planta ou célula de planta transformada com um polinucleotídeo, molécula de rna de fita dupla, composição, e, formulação de caldo completo ou composição de cultura de células
BR112012027994A2 (pt) anticorpo isolado, composição farmacêutica, ácido nucleico isolado, composições, célula hospedeira, métodos de tratar esclerose múltipla, artrite reumatoide, perda óssea osteolítica e câncer
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
BR112012024287A2 (pt) anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BR112012031847A2 (pt) cultura de produção para a produção fermentativa de butanol, método de produção de butanol, método para a produção de butanol, método para aumentar a tolerância de uma cultura de produção para a produção fermentativa de butanol e cultura de produção para produção fermentativa de butanol
MX354049B (es) Método rápido para la clonación y expresión de segmentos génicos de regiones variables de anticuerpos cognados.
BR112012015255A2 (pt) "anticorpo, composição farmaceutica, uso de um anticorpo,método de tramento ,ácido nucleico, vetor de espressão, célula hospedeira e método de produção de um anticorpo recobinante"
BRPI0819526B8 (pt) Sequência de ácido nucleico de precursor de mirna artificial, construção recombinante e método para reduzir a expressão de uma sequência alvo
WO2011100749A3 (en) Methods and materials for detecting viral or microbial infections
CL2011002360A1 (es) Anticuerpo anti-alfa5beta1; molecula de acido nucleico que codifica el anticuerpo;celula huesped; metodo para produccionde anticuerpos anti-alfa5beta1; inmunoconjugado que comprende el anticuerpo; composicion farmaceutica.
EP4282881A3 (en) Antibodies against csf-1r
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
BR112014004193A2 (pt) célula hospedeira recombinante de trichoderma, métodos para produzir uma composição enzimática, composição enzimática, processos para degradar um material celulósico, para sintetizar um produto de fermentação e para fermentar um material celulósico
WO2012003402A3 (en) Compositions and methods for culturing microorganisms

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SEIKAGAKU CORPORATION (JP)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL